MYC amplification is associated with reduced tumor immunogenicity as assessed by the recovery of IR recombination reads from prostate cancer genomics ...
The U.S. Food and Drug Administration (FDA) today released New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4)(1) , a sweeping guidance that codifies multiple regulatory ...
A new research paper was published in Volume 13 of Oncoscience on February 7, 2026, titled “Reduced immunogenicity of MYC amplified, metastatic prostate cancer.” ...
SK bioscience announced that, together with IDT Biologika (IDT) and Australian biotechnology company Vaxxas, it has been ...
CHICAGO, Dec. 8, 2025 /PRNewswire/ -- Professor Sarfaraz K. Niazi, Ph.D., a leading authority in pharmaceutical sciences and internationally recognized biosimilars expert, has filed a major Citizen ...
Fifteen years have passed since the Biologics Price Competition and Innovation Act (BPCIA) transformed the biosimilar landscape. Today, we are at a crucial point: the FDA has finally removed clinical ...
In Canada, biosimilar biologic drugs (“biosimilars”) are biologic drugs demonstrated to be highly similar to an already authorized biologic product termed the Canadian Reference Biologic Drug (“CRBD”) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results